contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


eurocine-vaccines-decides-to-develop-mrna-based-vaccine-candidate-against-chlamydia

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Eurocine Vaccines operates in the pharmaceutical industry with a focus on developing vaccines for the global market. The company develops vaccine candidates from early innovation and licenses them to partners for further development and commercialization. The activities are carried out in the bioscience cluster at Karolinska Institutet in Solna, Sweden.

Eurocine Vaccines

In the pursuit of the most advanced vaccines of high potential, the board of Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using mRNA, the next generation vaccine...

<div class="abstract">In the pursuit of the most advanced vaccines of high potential, the board of Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using mRNA, the next generation vaccine technology. The technology enables development synergies with other vaccine candidates in our portfolio, gaining competitive edge with less investments. At the same time, the company decides to pause the resource-intensive development of the protein-based chlamydia candidate until further notice.</div>The success of mRNA vaccines in the Covid pandemic has fundamentally changed the way vaccines are developed. Being at the forefront in vaccine development, Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using the modern mRNA technology. The goal is to conduct preclinical studies and early mRNA development in the near term, to begin process development and other preparations in the fourth quarter of 2023, ahead of toxicological and then clinical trials. The resource-intensive development of the protein-based chlamydia vaccine candidate will be paused until further notice."mRNA-based vaccines have shown great clinical potential to drive both antibodies and T-cells, which is exactly what we aim for with our chlamydia vaccine. In addition, we see good opportunities to achieve synergies between our portfolio projects which use the same platform technology." says Dr. Karl Ljungberg, Head of Preclinical Development at Eurocine Vaccines.The mRNA-based vaccine candidate against chlamydia encodes for the same protein that has earlier been successfully documented and is covered by the same patent and exclusive global licensing agreement.&nbsp; This strengthens the conditions for success with the mRNA candidate.This information is such information that Eurocine Vaccines AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 17 January 2023.

Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Helsinki Stock Exchange is cheap

Valuation methods: Valuation multiples

Stay up to date with our newsletter